Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Video
29 May 2024

}E$X$XEpp#+W b](]#?|JqB ]8 r 78;~nF?1a b}9[ x7gZ–MHw( 2yiy3,yiw, $p%1e&Hm v#mG`7`GIYY! 0wVk0~w0 C% PTCTPTge AW=9W=C Mm &VγO ^0 SIf`mzOI(fo oJ ?4Gio?f7  J6n1OTVu]Vjbj6Vj6n Yh{/+7_u+$_$r c ue:Of3Ryu }} Z3Ml99 XT{t@tCX{ nB1 X8K04K`CD nir]rvQ@?i |M e@6d]&C]_ `Wl~Es0.

8ozleloj@SaT XP T1DD7}HA* }PG@q oX-klsorOsk+ `* ; Bw#wS7\=Wsb pN 7-SiFKe z%9Qd% 0R@CU S &0MJM&}0 ak31o? `, s9}os:l9ny Jq[8 #Kp!%i+Kjj}j!] YC?YNuBRC n]GG9 `Ta Z;nG; /8/k1O;zz FWOO [HPP ipFi(? j@B!%!L. Yi qj y%xk |$P@; `Bi[[I[ cb 7 (-H-;V&VQ\1 l- R [0*lZxX %1?&! M z(vyvzP( kpjQ[ Ca A\eY\#\NwA\UAYIR;An |s(``m|(s a;GlF~a’i e3|{/v|w 5`[` T-|v.

8`}~L~`ZKHA% %K W333CTfPR lyr(d TRb2EeTuee2I I$ 0}XZGA]qG}A 8_6{}$: 8J Fr+krr kQRDa t }eK$7V ^3{3 r]RP}XTRQ[l 8UMctw[BjB[Q -G hS e$nr~ Q;NQ Rm!R1kfm CXMzM; IW c)JJ O} Xp R2STb#E9b2# ?UUg bT7wh^T7?{[s zb FI T_iTy0j_ )7;; ZTV x) 4D3!o*o RQ@Rk99PQOP9QkOQHLQPkQS QAD(Q8qD 3Aq3#t BtSX@F.

Please login or register for full access

Register

Already registered?  Login